CAMBRIDGE, Mass.--(BUSINESS WIRE)--Last night at Symphony Hall in Boston, MA, PixarBio Corporation, the inventors of NeuroReleaseTM, a Morphine Strength, non-addictive pain treatment with US FDA approval expected in 2018, received the Boston Business Journal “2016 Best Places to Work” Award.
“We are extremely pleased to recognize these companies that clearly value their employees and go the extra mile to create great workplaces”
The award recognizes PixarBio as one of the Boston region firms offering the greatest professional opportunities and work environments. Companies are selected for many reasons, whether it’s PixarBio’s Red Sox tickets for every employee birthday, the chance to join a truly time-tested innovation engine in neuroscience, or the strong compensation packages, PixarBio was selected as one of the companies in the category for companies with 20 to 49 employees.
Carolyn M. Jones, market president and publisher of the Boston Business Journal recognized the companies saying, “We are extremely pleased to recognize these companies that clearly value their employees and go the extra mile to create great workplaces”. Winning companies were chosen through survey responses provided by employees of those companies.
“My RSB Model is time-tested. It’s my second win in the last three years with two different companies, so at PixarBio we say with confidence, ‘WE GOT THIS!’ This win is huge for our team, whom I’ve been working with for almost a decade. PixarBio will begin public trading in early Q3 2016, so the timing of this award is perfect. Recruiting has been easier the last month or so since announcing our award for ‘BBJ Best Place to Work’, and now we’ll recruit with the incentive of public stock options. It’s win-win for all stakeholders and patients. In 2017, we predict that we’ll be back to win the 100-249 Category as we scale our company to replace opioids/opiates in the clinic, and to alleviate post-operative rebound pain, from the healthcare system.” said PixarBio Co-Founder Frank Reynolds.
“It takes a unique and innovative work environment to change neuroscience forever, and to achieve what we have achieved in just 3 years. PixarBio employees enjoy unmatched resources to get the job done. We thank the Boston Business Journal for this recognition, as we strive to go onward and upward to develop treatments for pain, spinal cord injury, epilepsy and Parkinson’s disease!” said PixarBio Chief Technology Officer Dr. Jason Criscione.
About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.